Multicenter phase II study of Taxotere (docetaxel) administered weekly or every three weeks in combination with prednisone as second line chemotherapy in patients with hormone refractory prostate cancer (HRPC).
Phase of Trial: Phase II
Latest Information Update: 03 Feb 2010
At a glance
- Drugs Docetaxel; Prednisone
- Indications Prostate cancer
- Focus Therapeutic Use
- Sponsors Sanofi
- 31 Aug 2018 Biomarkers information updated
- 12 Jan 2007 Status change
- 12 Sep 2006 New trial record.